- Thrombopoietin: a novel candidate tumor marker for the diagnosis of ovarian cancer
-
Mermer T, Terek MC, Zeybek B, Ergenoglu , Yeniel AO, Ozsaran A, Zekioglu O
- KMID: 2177580
- J Gynecol Oncol.
- 2012 Apr;23(2):86-90.
- doi: 10.3802/jgo.2012.23.2.86
OBJECTIVE: To investigate the decisive role of preoperative serum thrombopoietin levels in the discrimination of benign and malignant ovarian pathologies and its value in the evaluation of treatment response. METHODS: Fifty... -
- CITED
-
- Close
- SHARE
-
- Close
- Granulocyte-colony stimulating factor decreases the extent of ovarian damage caused by cisplatin in an experimental rat model
-
Akdemir A, Zeybek B, Akman L, Ergenoglu , Yeniel AO, Erbas O, Yavasoglu , Terek MC, Taskiran D
- KMID: 2130122
- J Gynecol Oncol.
- 2014 Oct;25(4):328-333.
- doi: 10.3802/jgo.2014.25.4.328
OBJECTIVE: To investigate whether granulocyte-colony stimulating factor (G-CSF) can decrease the extent of ovarian follicle loss caused by cisplatin treatment. METHODS: Twenty-one adult female Sprague-Dawley rats were used. Fourteen rats were... -
- CITED
-
- Close
- SHARE
-
- Close
- Financial toxicity in patients with gynecologic malignancies: a cross sectional study
-
Zeybek B, Webster E, Pogosian N, Tymon-Rosario J, Balch A, Altwerger G, Clark M, Menderes G, Huang G, Azodi M, Ratner ES, Schwartz PE, Santin AD, Andikyan V
- KMID: 2526281
- J Gynecol Oncol.
- 2021 Nov;32(6):e87.
- doi: 10.3802/jgo.2021.32.e87
Objective To evaluate financial toxicity and assess its risk factors among patients with gynecologic cancers. Methods This is a cross sectional study that included 2 survey tools, as well as patient demographics, disease... -
- CITED
-
- Close
- SHARE
-
- Close
